 The use of multipotent stromal cells, MSCs, has shown promise in treating graft versus host disease and cardiovascular diseases. However, there is still much work to be done to ensure the quality and purity of manufactured cell batches. This paper examines the current state of research regarding the identification of MSCs based on surface markers and the identification of MSCs from bone marrow samples. It concludes by suggesting that certain markers such as CD271 and W8B2 MSCA1 could be used to identify MSCs in both animal and human studies. Large animal models are necessary to test the safety and efficacy of MSCs in tissue engineering applications. This article was authored by Sally A. Boxall and Elena Jones.